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Background: Niemann Pick C (NPC) disease is a neurovisceral lysosomal storage disorder due to mutations in NPC1
or NPC2 genes, characterized by the accumulation of endocytosed unesterified cholesterol, gangliosides and other
lipids within the lysosomes/late endosomes. Even if the neurodegeneration is the main feature of the disease, the
analysis of the molecular pathways linking the lipid accumulation and cellular damage in the brain has been
challenging due to the limited availability of human neuronal models.
Objective: The aim of this study was to develop a human neuronal model of NPC disease by inducing neuronal
differentiation of multipotent adult stem cells (MASC) isolated from NPC patients.
Methods: Stem cells were isolated from 3 NPC patients and 3 controls both from skin biopsies and previously
established skin fibroblast cultures. Cells were induced to differentiate along a neuronal fate adapting methods
previously described by Beltrami et al, 2007. The surface immunophenotype of stem cells was analyzed by FACS.
Stem cell and neuronal markers expression were evaluated by immunofluorescence. Intracellular accumulation of
cholesterol and gangliosides were assessed by filipin staining and immunofluorescence, respectively. A
morphometric analysis was performed using a Neurite outgrowth image program.
Results: After 3 passages in selective medium, MASC isolated either from skin biopsies or previously established
skin fibroblast cultures displayed an antigenic pattern characteristic of mesenchymal stem cells and expressed the
stem cell markers Oct-4, Nanog, Sox-2 and nestin. A massive lysosomal accumulation of cholesterol was observed
only in cells isolated from NPC patients. After the induction of neural differentiation, remarkable morphologic
changes were observed and cells became positive to markers of the neuronal lineage NeuN and MAP2.
Differentiated cells from NPC patients displayed characteristic features of NPC disease, they showed intracellular
accumulation of unesterified cholesterol and GM2 ganglioside and presented morphological differences with
respect to cells derived from healthy donors.
In conclusion, we generated a human neuronal model of NPC disease through the induction of differentiation of
stem cells obtained from patient’s easily accessible sources. The strategy described here may be applied to easily
generate human neuronal models of other neurodegenerative diseases.
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Niemann Pick C [NPC-MIM 257220; MIM607625] dis-
ease is a neurodegenerative lysosomal storage disorder
due to mutations in NPC1 or NPC2 genes, character-
ized by the accumulation of endocytosed unesterified
cholesterol, gangliosides and other lipids within the ly-
sosomes/late endosomes. Both proteins are involved in
the intracellular trafficking of cholesterol and other
lipids. Thus, the deficiency of either of them leads to the
accumulation of the endocytosed unesterified cholesterol,
gangliosides and other lipids within the lysosome/late en-
dosome compartment [1].
Clinically, NPC disease presents a highly variable
phenotype ranging from fetal to adult age. Even though
initial manifestations are typically systemic, including
liver and spleen enlargement, the disease has been classi-
fied according to the age at onset of neurological symp-
toms in: severe infantile form (onset before 2 y of age),
late infantile form (onset between 3-5 y of age), juvenile
form (onset between 5 and 16 y) and adult form (onset
at age>16 y) [1,2].
Approximately 95% of NPC patients present mutations
in NPC1 gene (MIM 607623; chr 18q11-q12) [3,4],
which encodes a membrane glycoprotein of 1,278 amino
acids containing 13 transmembrane domains and local-
ized in late endosomes [5]. The other 5% of patients
present mutations in NPC2 gene (MIM 601015; chr
14q24.3) [6] encoding a soluble 151 amino acid protein
that is present in the lumen of lysosomes.
Despite the progress in characterizing the biochemical
and genetic defects in NPC disease, the mechanisms
underlying the pathophysiology of this disorder are not
clear and the currently available therapeutic interven-
tions are limited. In particular, the analysis of the mo-
lecular pathways linking the lipid accumulation and
cellular damage in the brain has been challenging due to
the limited availability of neuronal models.
Two mouse models of NPC disease have been de-
scribed and used to study NPC pathogenesis, the
BALB\c NPC [7] and the Npc1 (nmf164) mouse [8].
The naturally occurring BALB\c NPC mouse recapit-
ulates the main features of human pathology [7].
However, while this model presents a very severe
phenotype, most NPC patients present with a less se-
vere form of the disease. This issue is particularly
relevant when this model is used to test new poten-
tial therapies since the very acute nature of the
BALB\c NPC mouse model may mask the potential
benefits of therapies that could be useful in a clinical
setting in patients. Recently, a new mouse model of
NPC disease, Npc1 (nmf164) carrying a c.3163A>G
mutation that results in an aspartate to glycine change
at position 1005 (D1005G), has been generated. This
mutant mouse displays a slower development of theNPC phenotype than the BALB\c NPC mouse. There-
fore, it may represent a good model for the late-onset,
slower progressing forms of NPC disease [8]. How-
ever, it is worth noting that some characteristic fea-
tures of NPC human neurons are not present in mice,
suggesting important species differences between mice
and human NPC neurons [9-11].
Many studies have been performed in peripheral cells
in culture. However, the obtained results might not be
extrapolated to neuronal cells since the pattern of accu-
mulated lipids is quite different between peripheral and
central tissues [12].
Recent advances in human stem cell biology and the
optimization of protocols for in vitro differentiation of
stem cells into different cell lineages have opened new
possibilities for generating disease cellular models.
Pluripotent cells have the ability to form all the body's
cell lineages, including germ cells and some extra-
embryonic cell types [13]. The analyisis of blastocyst
chimerism and tetraploid aggregation followed by gesta-
tion are the most appropriate tests employed to assess
mouse stem cell pluripotency [13]. Human stem cell
pluripotency cannot be tested for their ability to gener-
ate fully functional germ cells in vivo without raising
ethical concern. Consequently, a surrogate test for hu-
man stem cell pluripotency is teratoma formation upon
administration to a receptive animal [13]. Interestingly,
a number of reports have demonstrated that adult hu-
man tissues host widely multipotent cells. Although
these latter are able to differentiate, both in vitro and
in vivo [13,14], into mesodermal [15], ectodermal [16]
and endodermal [17] derivatives, even at a clonal level
[18], they do not form either teratomas in vivo or con-
tribute to the germ cell lineages, thus not entirely ful-
filling the criteria for pluripotency. This may be
secondary to epigenetic differences between adult and
embryonic stem cells [14].
Our group has described a highly reproducible method
to isolate, from different adult human tissues (heart, liver
and bone marrow), a population of multipotent stem
cells (named Multipotent Adult Stem Cells or MASC),
which express several pluripotent state specific tran-
scription factors (i.e. OCT4, Nanog, Sox2, and Rex1),
display high levels of telomerase activity and show all
the characteristics of stem cells, such as clonogenicity
and self renewal. Furthermore, they present a highly
similar gene expression profile, irrespectively from the
tissue of origin and they maintain the ability to differen-
tiate along some derivatives of the 3 germ layers, includ-
ing neuroectoderm [19].
The aim of this study was to develop a human neur-
onal model of NPC disease by inducing neuronal differ-
entiation of stem cells isolated from skin biopsies or
fibroblasts in culture obtained from NPC patients.
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Human samples
Specimens from 3 patients affected by NPC disease (two
of them were siblings) and 3 normal controls have been
used in this study. Samples from a patient affected by
Sandhoff disease were used as positive control for gan-
glioside accumulation assays.
All 3 NPC patients presented the classical biochem-
ical phenotype characterized by massive lysosomal/
late endosomes accumulation of unesterified choles-
terol in cultured fibroblasts. The diagnosis was con-
firmed by sequencing both NPC1 and NPC2 genes.
All patients had mutations in the NPC1 gene. The two
affected siblings presented the c.3182T>C (P.I1061T)/
c.3182T>C (p.I1061T) genotype, while the third unre-
lated NPC patient presented the c.2795+1G>C/
c.3493G>A (p.V1165M) genotype. This study was ap-
proved by the ethical committee of the University Hospital
“S. Maria della Misericordia” and written consent was
obtained from all subjects.
Stem cell selection and culture
Stem cell enriched cultures were obtained, both from
skin biopsies and from already established skin fibroblast
cultures at early passages (P1, P2, P3), adapting the
methods previously described [19,20].
Briefly, skin biopsies were minced and digested with
0.04% of collagenase type I (Sigma-Aldrich) for 15 minutes
at 37°C. Cell suspension was filtered through a 40 μm
nylon membrane (Dako) and 4 × 104 cells/mm2 were
plated onto fibronectin coated dishes (10 μg/100 mm plate,
from Sigma-Aldrich). In alternative, 2 × 106 cells directly
isolated from human skin biopsies or 1 × 106 cells
obtained from confluent primary skin fibroblast cultures,
were seeded onto 100 mm plates coated with fibronectin
and expanded at least for three passages in a selective
media composed of 60% Dulbecco’s Modified Eagle
medium (DMEM)/40% MCDB-201 (Sigma-Aldrich)
supplemented with 1 mg/ml Linoleic Acid-BSA (Sigma-
Aldrich);10-9 M dexamethasone (Sigma-Aldrich); 10-4 M
Ascorbic acid-2 phosphate (Sigma-Aldrich); 1X Insulin-
transferrin-sodium selenite (Sigma-Aldrich); 2% fetal bo-
vine serum (FBS), (STEMCELL Technologies), 10 ng/ml
human PDGF-BB (Peprotech EC); 10 ng/ml human EGF
(Peprotech EC). Medium was replaced every 4 days and
cells were split when they reached 70/80% confluence.
Single cell cloning
Stem cells, at the third passage in culture (P3), obtained
from healthy donors (n = 600 cells) and NPC patients
(n = 600 cells) were individually deposited directly
into fibronectin-coated wells of 96-well plates (Falcon,
BD-Biosciences, Italy) with an automated cell sorter
(FACSAria, BD), and cultured in expansion mediumsupplemented with 10% FBS [19,20]. To determine
sorting efficiency and to verify if any well was seeded
with more than one cell, we utilized the Vybrant
CFDA SE (CFSE) as a cell tracker (Molecular Probes,
Invitrogen). Wells were examined twice a week in
order to determine the fraction of cells able to give
rise to proliferating clones.
Multilineage differentiation
Multilineage differentiation was evaluated as previously
described [19,20].
Muscle cell- and endothelial cell- differentiation was
achieved plating 0.5 to 1 × 104/cm2 cells in expansion
medium containing 5% FBS (Sigma-Aldrich), 10 ng/mL
bFGF, 10 ng/mL VEGF, and 10 ng/mL IGF-1 (all from
Peprotech EC), but not EGF. Cells were allowed to be-
come confluent and cultured for up to 2 weeks with
medium exchanges every 4 days.
Hepatocytic differentiation was induced growing cells
for two weeks at high density (2 × 104/cm2) onto fibro-
nectin coated coverslips in a medium containing 0.5%
FBS, 10 ng/ml FGF-4 and 20 ng/ml HGF (both from
Peprotech EC).
For neurogenic differentiation, stem cells obtained after
3 passages in selective medium, were seeded at a density
of 8000 cells/cm2 into 96 multiwell plates (BD Biosci-
ences) or on coverslips. The differentiation protocol was
adapted from a method previously described [19,20].
Briefly, cells were plated in medium containing DMEM-
HG with 10% FBS (called N1 medium). After 24 hours
the DMEM-HG was replaced with fresh medium
supplemented with 1% of B27 (Invitrogen), 10 ng/ml
EGF (Peprotech) and 20 ng/ml bFGF (Peprotech) (called
N2 medium) for 5 days. Thereafter, cells were incubated
for 24/48 hours in DMEM supplemented with 5 μg/ml
insulin, 200 μM of indomethacin and 0.5 mM IBMX (all
from Sigma-Aldrich) without FBS (called N3 medium).
Flow cytometry analysis
After at least 3 passages in selective medium, stem cells
were detached and stained with the following primary
conjugated antibodies: CD10, CD13, CD29, CD49a,
CD49b, CD49d, CD90, CD73, CD44, CD45, HLA-DR,
CD117, CD34, CD271 (BD Biosciences), CD105, CD66e,
KDR (Serotech), CD133 (Miltenyi Biotec), CXCR4, (R&D),
ABCG-2 (Chemicon International). The percentage of cells
expressing all considered antigens was determined by flow
cytometry analysis (CyAn, Beckman Coulter). Properly
conjugated isotype matched antibodies were used as nega-
tive controls.
Filipin staining
Filipin staining was performed using the method described
by Blanchette-Mackie et al. [21]. Briefly, cells grown on
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24 hours and then treated for 24 hours with LDL
enriched medium. Cells were rinsed with PBS and
fixed with 3% paraformaldehyde. After washing them
with PBS, the cells were incubated with 1.5 mg of
glycine/ml PBS for 10 minutes, stained with filipin
(0.05 mg/ml, in PBS 10% FCS) for 2 hours and ex-
amined using a Zeiss fluorescence microscope.
Periodic acid Schiff staining (PAS)
PAS was employed to detect glycogen accumulation. Slides
were oxidized in 1% periodic acid for 5 minutes, rinsed
three times in distilled water and treated with Schiff ’s re-
agent for 25 minutes. After extensive washing, slides were
stained with Mayer’s hematoxylin for 10 minutes.
Immunofluorescence microscopy
Protein markers: Cells were grown on coverslips then
fixed in 4% paraformaldehyde for 20 minutes at
room temperature, permeabilized 10 minutes at room
temperature with 0.1% Triton X-100 (Sigma-Aldrich)
and stained overnight at 4°C to visualize stem cell
markers: Oct4 (Abcam, Rabbit polyclonal, 1:150), Nanog
(Abcam, Rabbit polyclonal, 1:200), Sox2 (Millipore, Mouse
monoclonal, 1:200), Nestin (Millipore, 1:100); myocytes
specific markers: smooth muscle actin (SMA) (Sigma, 1:50
mouse monoclonal) and α-sarcomeric actin (ASA) (Sigma,
1:100 mouse monoclonal); endothelial cell marker: CD31
(Dako, 1:50 mouse monoclonal); hepatic specific marker:
cytokeratins 8, 18, and 19 (CK) (1:50 mouse monoclonal);
or neural specific markers: tubulin beta 3 (COVANCE,
1:1000 mouse monoclonal), NeuN, (Millipore, 1:50 mouse
monoclonal) and MAP2 (Millipore, 1:50 rabbit polyclonal).
Secondary antibody staining was done with donkey anti-
rabbit or donkey anti-mouse antibodies (Alexa-Fluor 555
or 488, Molecular Probes) at 1:600 dilutions. Images were
obtained with a live cell imaging dedicated system
consisting of a Leica DMI 6000B microscope connected to
a Leica DFC350FX camera (Leica Microsystems); 10X
(numerical aperture: 0.25), 40X oil immersion (numerical
aperture: 1.25) and 63X oil immersion (numerical aper-
ture: 1.40) objectives were employed.
GM2 and GM3 analysis: The analysis of GM2 and
GM3 gangliosides was performed as previously de-
scribed [22]. Cells were grown on coverslips then
fixed in 4% paraformaldehyde for 45 minutes at
room temperature. Cells were then incubated at room
temperature for 1 hour in blocking buffer [PBS with
10% normal donkey serum (NDS) and 0.02% saponin
(Sigma-Aldrich)] and stained overnight at 4°C with
mouse anti-GM2 (1:20 in blocking buffer) or mouse
anti-GM3 (1:20 in blocking buffer). Cells were then in-
cubated with a TRITC conjugated donkey anti-mouse
IgM [1:80 in PBS with 2% NDS and 0.02% saponin(Sigma-Aldrich)]. For colocalization studies, a mono-
clonal anti-LIMP-1 (Novus Biologicals, Littleton, USA)
was used as a primary antibody, and an Alexa fluor-
conjugated anti-mouse (Invitrogen, Carlsbad, CA, USA) as
a secondary antibody.
In all cases, nuclei were stained by DAPI (Vector
Laboratories, Inc) and Vectashield (Vector) was used
as mounting medium. Epifluorescence and phase con-
trast images were obtained with a live cell imaging
dedicated system consisting of a Leica DMI 6000B
microscope connected to a Leica DFC350FX camera
(Leica Microsystems); 10X (numerical aperture: 0.25),
40X oil immersion (numerical aperture: 1.25) and 63X
oil immersion (numerical aperture: 1.40) objectives
were employed. Adobe Photoshop software was uti-
lized to compose and overlay the images, and adjust
contrast (Adobe, USA). The counts of positive cells
were done manually, considering, where possible, 100
positive events per sample.
Real-time RT-PCR
Total RNA was extracted from both non-confluent
cultures of undifferentiated and differentiated cells at
P3 using the TRIzol Reagent (Invitrogen). After treat-
ment with DNase I (Ambion), first strand cDNA syn-
thesis was performed with 1 μg total RNA using
random hexanucleotides and MMLV reverse transcript-
ase (Invitrogen). Primers were designed from available
human sequences using the primer analysis software Pri-
mer3 (Additional file 1: Table S1). Quantitative RT-PCR
was performed using Roche LightCycler 480 Real-Time
PCR System and the LightCycler 480 SYBR Green I Master
(Roche), following manufacturer’s instructions. GAPDH
was used as internal control for normalization. LightCycler
480 Basic software (Roche) utilized the second derivative
maximum method to identify the crossing point (Cp).
Evaluation of apoptosis
Apoptosis in differentiated cells at P3 was evaluated by
staining of phosphatidylserine exposed on cell membranes
with FITC labeled Annexin V, according to the manufac-
turer’s instructions (Sigma-Aldrich) and analyzed by flow
cytometry using a FACScan (Becton Dickinson, Franklin
Lakes, NJ, USA).
Morphological analysis
Morphological analysis data were collected by using the
BD Pathway bioimaging platform. Differentiated cells
were first immunostained for the neural marker MAP-2,
then images were acquired on a BD Pathway 855 using a
20X objective (0.75 NA) in the form of 2 × 2 montage.
The images were then analyzed using BD’s Neurite Out-
growth Algorithm that automatically measure parame-
ters describing neurite outgrowth.
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Statistical analysis was performed using Student’s t test
or one-way ANOVA test, followed by Bonferroni post-
test. The analyses were carried out using the software
Prism, version 4.0c, GraphPad Software, San Diego, CA,
USA; JMP7, SAS Institute Inc., Cary, NC, USA.
p<0.05 was considered statistically significant.
Results
Stem cell characterization
In order to isolate multipotent stem cells from NPC pa-
tient samples, we applied a protocol that was optimized for
the growth of widely multipotent cells with mesenchymal
features (named human multipotent adult stem cells-
hMASC) from several human tissues [19,20] to both
freshly obtained skin biopsies and previously established
skin fibroblast cultures. If successful, this latter strategy
would allow us to derive multipotent cells from already
available bio-repositories of cell lines, obtained from pa-
tients suffering from rare diseases, such as NPC, for diag-
nostic purposes.
When exposed to a selective culture medium enabling
the growth of hMASC, proliferating cell lines could be
obtained from all skin biopsies. On the contrary, only
those fibroblast cultures that had not been extensively
expanded in vitro (< 3 passages in vitro) were respon-
sive to these stringent culture conditions. After 3 pas-
sages in the selective medium, the cells acquired a
homogeneous morphology as shown in Figure 1A-D.
No differences were observed neither between cells
obtained from NPC patients and normal controls nor
between cells obtained from biopsies or from already
established skin fibroblast cultures.
In order to characterize the selected cells, their sur-
face immunophenotype was analyzed. As shown in
Figure 1E and Table 1, cells obtained both from skin
biopsies and fibroblast cell lines displayed an anti-
genic pattern characteristic of mesenchymal stem
cells, very similar to the one observed in MASC iso-
lated from heart, liver or bone marrow [19]. No major
differences were observed between cells derived from
NPC patients or normal controls.
Cultured cells were then evaluated for the expres-
sion of stem cell markers, such as the pluripotent
state specific transcription factors Oct-4, Nanog and
Sox-2 and the intermediate filament nestin. As shown
in Figure 1F-K, the vast majority of cells (65 to 90%)
expressed these markers and this expression was inde-
pendent from the disease state. In fact, no significant
differences were observed between NPC and normal
cells or between cells isolated from both skin biopsies
and early passages of fibroblast cell lines.
In order to investigate whether the pathologic
phenotype was retained in these cells, the intracellularaccumulation of unesterified cholesterol was analyzed
by filipin staining. A massive accumulation of choles-
terol within the endosomal/lysosomal compartment
was observed in cells isolated from either skin biopsies
or fibroblast cultures of NPC patients (Figure 1L-N).
Therefore, in the light of these data, we decided to
further characterize stem cells derived from already
established skin fibroblast cultures and use them to
develop a neuronal differentiation model.
Cell cultures showed two of the major features of
multipotent adult stem cells such as clonogenicity and
wide differentiation capacity. Specifically, when sorted
as single cells into the wells of 96-well Terasaki
plates, skin-derived cells were able to form proliferat-
ing colonies within 2 weeks after seeding. It is worth
noting that cells derived from NPC patients seem to
be less clonogenic than cells derived from healthy
controls. Even if the differences were not statistically
significant, this result suggests that some stem cells fea-
tures may be compromised in NPC disease. The cells
were able to differentiate along derivatives of all the
three germ layers (Figure 2, Additional file 2: Figure S1
and Additional file 3: Figure S2). In this regard, cul-
tured cells generated not only neurectodermic deriva-
tives (see below) but mesodermal and endodermal ones
as well. Specifically, cells derived from both healthy
controls and NPC patients cultured in a medium added
with IGF-1, bFGF and VEGF expressed the myocyte
specific markers alpha-sarcomeric actin (ASA) and
smooth muscle actin (SMA) and the endothelial cell
marker CD31 (Additional file 2: Figure S1). Addition-
ally, cells exposed to hepatocyte differentiation medium
assumed a globular shape and became positive for
cytokeratins 8, 18, and 19 (CK). Moreover, they ac-
quired some hepatocitic functions such as the ability to
store glycogen as demonstrated by the PAS staining
(Additional file 3: Figure S2).
Altogether these results indicate that cells obtained from
fibroblast cultures of healthy controls and NPC patients
exhibited almost an identical mesenchymal stem cell
immunophenotype, expressed pluripotent state specific
transcription factors, were clonogenic and multipotent;
therefore, in analogy with our previous studies, we named
them hSKIN-MASC.
Neural differentiation
Twenty-four hours after the induction of neural differen-
tiation, hSKIN-MASC showed remarkable morphologic
changes. As shown in Figure 2 (panels A-B) differentiated
cells displayed an enlargement of the cellular bodies and
the presence of long projections, closely resembling the
morphology of neuronal cells. Importantly, the morph-
ology of differentiated cells obtained from NPC patients
and healthy donors was clearly distinct. In fact, with
Figure 1 Characterization of stem cell populations obtained from skin biopsies or already established skin fibroblast cultures. (A-D) Phase
contrast images of hSKIN-MASC at the third passage in culture: A-B) hSKIN-MASC obtained from skin biopsies of a healthy donor (A) and a NPC patient
(B). C-D) hSKIN-MASC obtained from already established skin fibroblasts from healthy donor (C) and NPC patient (D). (E) Surface immunophenotype:
representative flow cytometry histograms of skin derived stem cell cultures. Plots show isotype control IgG-staining profile (green histograms) versus
specific antibody staining (red histograms). (F-H) Pluripotent state specific transcription factor expression: representative fluorescence images of Oct-4
(green fluorescence; F), Nanog (green fluorescence; G) and Sox-2 expression (green fluorescence; H) localized in the nuclei of skin derived stem cell
cultures. Nuclei are depicted by the blue fluorescence of DAPI staining (F-H). I) Quantification of the percentage of cells expressing Oct4 (white bars),
Nanog (black bars) and Sox-2 (gray bars) in hSKIN-MASC obtained both from healthy donors (CTRL, n = 3) and NPC (n = 3) skin biopsies or healthy
donors (CTRL, n = 3) and NPC (n = 3) skin fibroblast cultures. At least 400 cells have been counted for each cell line. Data are presented as mean ± SD of
3 independent experiments. (J-K) Nestin expression (red fluorescence) in hSKIN-MASC obtained from a healthy donor (J) and a NPC patient (K). (L-N)
Unesterified cholesterol accumulation: images obtained after performing the filipin staining (blue fluorescence) in hSKIN-MASC derived from a healthy
donor skin biopsy (L), a NPC patient skin biopsy (M) and a NPC skin fibroblast cell line (N), respectively.
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obtained from NPC patients (Figure 2B) were larger and
presented numerous projections similar to dendrites.
Upon differentiation, a large fraction of hSKIN-MASC
became positive to markers of the neuronal lineage. In
particular, they expressed NeuN (Figure 2C-E), a neur-
onal specific nuclear protein, and MAP2 (Figure 2F-H),
a structural protein specifically present in neuronal cells.
Interestingly, the percentage of cells expressing NeuN
was significantly lower in cells derived from NPC pa-
tients than in cells derived from healthy donors. In
addition, differentiated cells did not express markers as-
sociated with glial differentiation, such as glial fibrillaryacidic protein (GFAP) and oligodendroglial protein 4
(O4) (data not shown). These data suggest that the differ-
entiation protocol described here specifically favored the
differentiation towards the neuronal lineage. It is worth
noting that, after differentiation, the cells became nega-
tive for the pluripotent state specific transcription factors
Oct-4, Nanog and Sox-2, while the expression of nestin
was maintained throughout the differentiation process.
To further characterize the type of neuronal cells
obtained, mRNA expression of specific markers of
dopaminergic (tyrosine hydroxylase, TH and dopamine
transporter, DAT), cholinergic (choline acetyltransferase,
CHAT) and GABAergic (glutamic acid decarboxylase,
Table 1 Surface immunophenotype of stem cells isolated from skin biopsies or culture fibroblasts
Healthy donor (skin biopsy) NP-C (skin biopsy) Healthy donor (fibroblast culture) NP-C (fibroblast culture)
CD49d 95.9 ± 3.2 99.89 ± 0.22 99.1 ± 0.7 99.9 ± 0.08
CD49a 37.5 ± 7.2 48.6 ± 0.4 6.38 ± 2.51 54.18 ± 3.44
CD49b 96.48 ± 2.8 99.21 ± 0.3 99.98 ± 0.1 99.95 ± 0.2
CD29 43.33 ± 12.5 62.75 ± 1.05 17.05 ± 14.7 17.62 ± 4.9
ABCG2 1.57 ± 0.7 1.14 ± 0.02 1.81 ± 0.06 1.37 ± 0.25
CXCR4 0.22 ± 0.1 0.16 ± 0.01 0.081 ± 0.06 0.18 ± 0.05
CD10 77.8 ± 13 98 ± 0.4 55.5 ± 20.7 96.05 ± 1.2
CD66 1.23 ± 0.7 3.04 ± 0.05 0.72 ± 0.7 0.28 ± 0.23
CD133 2.06 ± 0.34 5.88 ± 0.28 0.31 ± 0.08 0.23 ± 0.12
CD271 2.95 ± 1.33 0.2 ± 0.071 0.37 ± 0.31 0.89 ± 0.24
CD44 95.89 ± 2.7 97.25 ± 0.2 99.41 ± 0.7 98.94 ± 1.02
CD105 87 ± 3.4 85.9 ± 2.78 92.73 ± 4.35 74.92 ± 30.8
CD90 97.12 ± 3.2 98.88 ± 1.41 99.52 ± 0.28 96.25 ± 3.7
CD73 92.9 ± 3.7 99.75 ± 0.08 99.48 ± 0.4 99.7 ± 0.19
CD34 3.7 ± 1.7 1.9 ± 0.1 0.205 ± 0.12 0.66 ± 0.83
CD45 0.1 ± 0.2 0.19 ± 0.01 0.45 ± 0.04 0.07 ± 0.02
KDR 3.12 ± 1.1 1.47 ± 0.03 1.92 ± 2.18 1.53 ± 0.18
CD13 98.49 ± 3.7 98.4 ± 1.9 99.78 ± 0.21 99.88 ± 0.15
CD117 1.1 ± 0.67 0.52 ± 0.03 0.15 ± 0.13 0.27 ± 0.3
HLA-DR 0.37 ± 0.1 0.12 ± 0.14 0.65 ± 1.01 0.03 ± 0.01
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of these markers were detected in undifferentiated cells.
After differentiation, both cells derived from healthy
donors and NPC patients expressed similar levels of
CHAT mRNA (Additional file 4: Figure S3), while the
levels of TH, DAT and GAD mRNA were undetectable.
No differences in the levels of apoptosis have been
detected between differentiated cells derived from healthy
donors and NPC patients (Additional file 5: Figure S4).
To determine whether neuronal cells obtained from
NPC patients retained the characteristic NPC phenotype,
intracellular accumulation of cholesterol and gangliosides
was analyzed by filipin staining and immunofluorescence,
respectively. As shown in Figure 3, a massive accumulation
of unesterified cholesterol was found in the bodies of dif-
ferentiated cells obtained from NPC patients (Figure 3B).
Furthermore, a percentage of these cells accumulated
GM2 ganglioside as well (Figure 3D). Interestingly, the per-
centage of GM2 positive cells obtained applying the neur-
onal differentiation protocol to hSKIN-MASC from either
NPC patients or a patient affected by Sandhoff disease was
comparable (Figure 3F). GM2 accumulation was acquired
during the differentiation process since this ganglioside
could not be detected both in NPC fibroblasts (data not
shown) and in undifferentiated hSKIN-MASC (Figure 3C).
No accumulation of GM3 was detected both in normal
and NPC cells (data not shown).Morphologic analysis of neuronal cells
As mentioned above, NPC differentiated cells presented
a morphology that was clearly different from normal
cells. Therefore, in order to quantify the morphologic dif-
ferences observed, we analyzed the neurite maximal and
average length, neurite extremity, segment and root
count and neurite node points, using the Neurite out-
growth image program on cells that stained positive for
MAP-2. Statistically significant differences were found
for all the analyzed parameters between normal and NPC
neuronal cell. As shown in Figure 4, NPC differentiated
cells presented longer neurites and a greater number of
neurite extremities, segments, roots and node points.
Discussion
The remarkable advances in the ability to obtain stem
cells from different tissues, including skin (reviewed in
[13,14] and [23]), which are able to differentiate into
several cell lineages, offer the possibility to generate
cells with neuronal characteristics from easily access-
ible sources.
It is conceivable then to develop human cellular
models for the study of neurodegenerative diseases
harvesting cells from skin biopsies of affected patients
and committing them to a neuronal fate, thus paving the
way to the study of pathways involved in the develop-
ment of neurological diseases at the cellular level.
Figure 2 Neural differentiation of hSKIN-MASC obtained from already established skin fibroblast cultures. (A-B) Phase contrast images of
hSKIN-MASC after induced to differentiate toward a neuronal fate (5 days in N2 medium + 48 h in N3 medium, see methods) from a healthy donor
(A) and a NPC patient (B). (C-H) Neuronal markers detection: differentiated cells (5 days in N2 medium + 48 h in N3 medium, see methods),
obtained from a healthy donor (C, F) or a NPC patient (D, G), express the neuron specific markers NeuN (yellow fluorescence, C, D) and MAP2
(green fluorescence, F, G). Nuclei are depicted by the blue fluorescence of DAPI staining. Quantitative evaluation of the percentage of cells
expressing NeuN (E) or MAP2 (H) in cultures from healthy donors (CTRL, n = 3) and NPC patients (n = 3) skin fibroblast derived cultures, before
(Undiff.) and after the exposure to neuron induction media (Diff.). At least 400 cells have been counted for each cell line. Data are presented as mean ±
SD of 3 independent experiments one-way Anova test followed by Bonferroni post-test were utilized to compare means between groups. P values less
than 0.05 were considered significant. P values less than 0.05 were considered significant. *, **, ***, p<0.05 vs. columns 1, 2, and 3, respectively.
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http://www.ojrd.com/content/8/1/34NPC is a genetic severe neurodegenerative disease
characterized by the accumulation of cholesterol and
other lipids within the late endosomes and lysosomes.
Although the neuronal degeneration is the main feature
in NPC patients, the molecular pathways linking the
lipid accumulation and cellular damage in the central
nervous system are largely unknown.
Therefore, we developed a human neuronal model of NPC
disease using a method based on the induction of neuronal
differentiation of stem cells isolated from skin biopsies or pri-
mary cultures of fibroblasts obtained from NPC patients.
Here, we demonstrated that it is possible to isolate
clonogenic adult stem cells expressing mesenchymal and
pluripotent state associated markers both from skin bi-
opsies and fibroblast cultures. In analogy with the
multipotent adult stem cells that we have previously iso-
lated from several adult human tissues, these cells were
widely multipotent, being able to differentiate into deriv-
atives of the three germ layers [19,20]. For these reasons
we named them hSKIN-MASC. The fact that we could
obtain multipotent stem cells only from early passages of
fibroblasts suggests that immature progenitors may beretained in those cultures but are lost upon serial expan-
sion in vitro.
In particular, cells differentiated to neuronal fate
expressed markers of mature neurons (NeuN and MAP2)
and displayed morphological features resembling neuronal
cells. It is worth to highlight that nestin, a marker of the
early ectoderm lineage, was expressed both in neural stem
cells and in hSKIN-MASC. These data suggest that
hSKIN-MASC may represent a population of cells that
share some features with the ectoderm lineage. This ob-
servation also suggests a common origin between hSKIN-
MASC and Skin-derived Precursors or SKP, a multipotent
cell population isolated from human dermis that shows a
differentiation potential towards both mesenchymal and
neural lineages. SKP are believed to be of neural-crest ori-
gin [24] and are retained throughout adulthood, although
they decrease with age [25].
A preliminary characterization of the type of neuronal
cells generated by this method, suggests that under the
experimental conditions described, hSKIN-MASCs dif-
ferentiated to cholinergic but not to dopaminergic or
GABAergic neurons.
Figure 3 Pathologic accumulation of unesterified cholesterol and GM2 in differentiated hSKIN-MASC derived from NPC patients. (A -B)
co-immunostaining for the lysosome marker Limp 1 (red fluorescence) and for unesterified cholesterol (blue fluorescence), revealed lysosomal
accumulation of cholesterol after neuronal differentiation (5 days in N2 medium + 48 h in N3 medium, see methods) only in cultures derived
from an NPC patient (B), but not in healthy donor derived cells (A). (C-F) Expression and relative quantification of the glycosphingolipid GM2 by
immunofluorescence: co-immunostaining for the lysosome marker Limp 1 (green fluorescence) and for GM2 (red fluorescence), revealed
accumulation of the ganglioside only in differentiated cultures derived from NPC (D) and Sandhoff (E) patients, but not in healthy donor derived
cells (C). F) The percentage of GM2 expressing cells was assayed in undifferentiated cells and after exposure to the neural inductive media
(5 days in N2 medium + 48 h in N3 medium, see methods), and compared to cells obtained in the same way but from a patient affected by
Sandhoff disease, a specific GM2 gangliosidosis. No GM2 accumulation was detected in both healthy controls (CTRL, n = 3) and NPC (n = 3)
undifferentiated cells, whereas a significant fraction of differentiated NPC (n = 3) and GM2 gangliosidosis derived cells showed accumulation of
the glycosfingolipid. At least 400 cells have been counted for each cell line. Data are presented as mean ± SD of 3 independent experiments;
one-way Anova test followed by Bonferroni post-test were utilized to compare means between groups. P values less than 0.05 were considered
significant. *, **, ****, p<0.05 vs. columns 1, 2 and 4, respectively. The Sandhoff patient was omitted from the statistical analysis.
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http://www.ojrd.com/content/8/1/34Differentiated cells obtained from NPC patients showed
some characteristic features of NPC phenotype. They ac-
cumulate unesterified cholesterol and GM2 ganglioside.
The accumulation of GM2 ganglioside observed in the dif-
ferentiated cells but not in fibroblasts or undifferentiated
hSKIN-MASC, is consistent with data previously reported
in NPC patients and NPC mouse models [10,12,26-29].
However, while these studies reported that NPC neuronal
cells also accumulate relevant amounts of GM3 ganglio-
side, no significant accumulation of this ganglioside was
found in our model. Since it has been described that
the accumulation of GM2 in the brain precedes the ac-
cumulation of GM3 [10], it is possible to hypothesize
that the model developed here recapitulates the early
stage of the disease.Furthermore, differentiated cells obtained from NPC
patients displayed morphological features that are clearly
different from those observed in cells obtained from
healthy donors, such as the presence of longer neurites
and a greater number of neurite extremities, segments,
roots and node points. Interestingly, a distortion of the
neuronal shape and an extensive growth of new ectopic
neurites have been observed in cortical neurons obtained
from human patients or animal models of NPC [29,30].
In addition, although there is no clear loss of cholinergic
neurons in NPC mice, it has been shown that in these
animals cholinergic neurons display several morpho-
logical alterations [31].
The identification of morphological alterations in dif-
ferentiated NPC cells that seem to recapitulate what has
Figure 4 Morphometric analysis of differentiated cells obtained from hSKIN-MASC of healthy donors or NPC patients. (A- B): Phase contrast
image showing the morphological differences between differentiated cells (5 days in N2 medium + 48 h in N3 medium, see methods) of a healthy
donor (A) and a NPC patient (B). Specifically, NPC differentiated cells were characterized by distortion of neuron shape, ectopic neurites and meganeurite
formation. (C): Quantitative analysis of neuronal morphological parameters linked to neurite outgrowth as evaluated by a specific Image analysis software
on MAP-2 stained cells. Data are presented as mean ± SD of 3 independent experiments; §, p<0.01 vs healthy donors (CTRL).
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http://www.ojrd.com/content/8/1/34been described in human cortical NPC neurons is cer-
tainly fascinating. However, we cannot exclude that this
phenotype is secondary to an impaired/altered differenti-
ation of MASC isolated from NPC patients. Indeed, the
lower percentage of cells expressing NeuN obtained after
differentiation of hSKIN-MASC isolated from NPC pa-
tients seems to support this hypothesis. Further studies
are planned to dissect the molecular mechanisms in-
volved in this phenomenon.
Recently, two human cellular models of NPC disease
have been developed by the specific silencing of NPC1
gene in the SH-SY5Y cells line [32] or in human embryonic
stem cells [33]. Both models recapitulate the NPC bio-
chemical phenotype. Although neuronal models obtained
through the down-regulation of NPC1 expression in hu-
man cells may be useful to analyze some aspects of NPC
pathogenesis, they are not suitable for the analysis of the
impact of specific mutations on the pathologic phenotype
or for testing mutation specific therapeutic strategies.The model described here offers three main advantages
with respect to the models cited above: 1-it was developed
directly from patient’s cells and therefore it would be useful
to analyze the effect of specific NPC1 mutations within the
context of the patient genetic/epigenetic background; 2-it
was obtained through the differentiation of cells obtained
from accessible sources, such as patients cultured fibro-
blasts, usually available in many laboratories for diagnostic
purposes; 3-it did not involve the forced expression of
transgenes in target cells, thus avoiding confounding re-
sults due to the reprogramming process.
Conclusion
We have demonstrated that it is possible to isolate stem
cells from skin biopsies or fibroblasts in culture and to
commit them to a neuronal lineage. Differentiated cells
obtained from NPC patients present the main features
of NPC disease. Therefore, this model will be useful to
study the molecular basis of NPC neurodegeneration
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http://www.ojrd.com/content/8/1/34and might represent a powerful tool to perform drug
screening on cells obtained from NPC patients present-
ing different genotypes. In addition, the strategy de-
scribed here may be applied to easily generate human
neuronal models of other neurodegenerative diseases.
Additional files
Additional file 1: Table S1. Sequences of oligonucleotides used for
real-time PCR.
Additional file 2: Figure S1. Mesodermic differentiation of hSKIN-MASC
obtained from already established skin fibroblast cultures (hSKIN-MASC). (A-B)
Phase contrast images of healthy donor- (A) and NPC patient- (B) derived
hSKIN-MASC after exposure to a medium added with IGF-1, bFGF and VEGF.
(C-F) Myocyte marker detection: differentiated cells, obtained from healthy
donor (C,E) or NPC patient (D,F), express the myocyte specific markers alpha-
sarcomeric actin (ASA) (red fluorescence, C,D) and smooth muscle actin
(SMA) (red fluorescence, E,F). (G-H) Endothelial cell marker detection:
differentiated cells, obtained from healthy donor (G) or NPC patient (H)
express CD31 (red fluorescence, G,H). Nuclei are depicted by the blue
fluorescence of DAPI staining. (I) Quantitative evaluation of the percentage of
cells expressing ASA (i), SMA(ii) and CD31(iii) in cultures from healthy donors
(CTRL, n = 3) and NPC patients (n = 3), before (Undiff.) and after exposure to
myocyte differentiation induction media (Diff.). At least 400 cells have been
counted for each cell line. Data are presented as mean±SD; one-way Anova
test followed by Bonferroni post-test was utilized to compare means
between groups. *, **, ***, p<0.05 vs columns 1,2 and 3, respectively.
Additional file 3: Figure S2. Hepatic differentiation of hSKIN-MASC
obtained from already established skin fibroblast cultures. (A-B) Phase
contrast images of healthy donor- (A) and NPC patient- (B) derived hSKIN-
MASC after differentiation into hepatocytes. (C-F) Hepatic markers detection:
differentiated cells, obtained from healthy donor (C,E) or NPC patient (D,F)
express the hepatocytes specific markers cytokeratins 8-18-19 (red
fluorescence, C,D) and stained positive for the Periodic Acid-Shiff (PAS)
staining (pink stain, E,F). Nuclei are depicted by the blue fluorescence of DAPI
staining (C, D) or by the blue-stain of hematoxylin (E, F). (G) Quantitative
evaluation of the percentage of cells expressing CK in cultures from healthy
donors (CTRL, n = 3) and NPC patients (n = 3), before (Undiff.) and after
exposure to hepatocytes differentiation induction media (Diff.). At least 400
cells have been counted for each cell line. Data are presented as mean±SD;
one-way Anova test followed by Bonferroni post-test were utilized to
compare means between groups. P values less than 0.05 were considered
significant. *, **, p<0.05 vs column 1 and 2, respectively.
Additional file 4: Figure S3. Relative expression of CHAT mRNA in cells
derived from healthy donors and NPC patients. The relative abundance of
CHAT mRNA were analyzed by real time PCR in cultures from healthy donors
(CTRL, n = 3) and NPC patients (n = 3), before (Undiff.) and after neuronal
differentiation (Diff.; 5 days in N2 medium + 48 h in N3 medium, see
methods). Data were normalized by the expression of GAPDH and expressed
as mean as mean ± SD of 3 independent experiments.
Additional file 5: Figure S4. Apoptosis in differentiated hSKIN-MASC
derived from healthy donors and NPC patients. After induction of neural
differentiation (5 days in N2 medium + 48 h in N3 medium, see
methods) the levels of apoptosis were evaluated in cultures derived from
healthy donors (CTRL, n = 3) and NPC patients (n = 3). Data are
presented as mean ± SD of 3 independent experiments.
Abbreviations
NPC: Niemann Pick C; MASCs: Multipotent adult stem cells; FBS: Fetal bovine
serum; DMEM: Dolbecco’s Modified Eagle Medium; BSA: Albumin from
bovine serum; PDGF: Platelet derived growth factor; EGF: Epidermal growth
factor; bFGF: Basic fibroblast growth factor; VEGF: Vascular endothelial
growth factor; IGF1: Insulin-like growth factor 1; HGF: Hepatocyte growth
factor; NDS: Normal donkey serum; PAS: Periodic acid Schiff staining;
CD31: Platelet endothelial cell adhesion molecule; SMA: Smooth muscle
actin; ASA: α-sarcomeric actin; CK: Cytokeratins; MAP2: Microtubule-
associated protein 2; GFAP: Glial fibrillary acidic protein; O4: Oligodendroglialprotein 4; TH: Tyrosine hydroxylase; DAT: Dopamine transporter;
CHAT: Choline acetyltransferase; GAD: Glutamic acid decarboxylase;
hMASC: Human multipotent adult stem cells; hSKIN-MASC: Human
multipotent adult stem cells derived from skin biopsies and fibroblast
cultures; SKP: Skin-derived Precursors.
Competing interest
The authors declare that they have no competing interests.
Authors’ contribution
NB: performed the experiments and the statistical analysis. AD: conceived
the idea and drafted the manuscript. A B: designed the experiments and
helped to draft the manuscript. DC: designed the experiments and helped to
draft the manuscript. SR: performed the experiments. SZ: performed the
cholesterol and glycolipid analysis. RD: performed the single cell and
multipotency experiments. BB: Provide clinical assistance and helped to draft
the manuscript. CAB: Coordinate and directed the study. All authors read
and approved the final manuscript.
Acknowledgments
The authors would like to thank Dr. Konstantin Dobrenis for providing anti-
GM2 and anti-GM3 antibodies. This work was supported by the Italian
Association of Niemann Pick,a grant from the Italian Health Ministry “Role of
protein misfolding in the pathogenesis of Niemann-Pick type C disease:a
possible therapeutic target (RF-2009-1524462)” and a grant from Italian
Health Ministry GR-2007-683407.
Author details
1Department of Medical and Biological Sciences (DSMB), University of Udine,
P.le Kolbe 3, 33100, Udine, Italy. 2Regional Coordinator Centre for Rare
Diseases, University Hospital “Santa Maria della Misericordia”, Udine, Italy.
Received: 7 September 2012 Accepted: 14 February 2013
Published: 21 February 2013
References
1. Patterson M, Vanier MT, Suzuki K, Morris ED, Cartsea EB, Neufeld EJ,
Blanchette-Mackie PG, Pentchev: Niemann Pick disease type C: a lipid
trafficking disorder. In The metabolic and molecular basis of inherited
diseases, Volume 3. VIIth edition. Edited by Scriver CR, Beaudet AL, Sly WS,
Valle D. New York: Mc Graw-Hill; 2001:611–634.
2. Vanier MT, Millat G: Niemann-Pick disease type C. Clin Genet 2003,
64:269–281.
3. Carstea ED, Polymeropoulos MH, Parker CC, Detera-Wadleigh SD, O'Neill RR,
Patterson MC, Goldin E, Xiao H, Straub RE, Vanier MT, Roscoe OB, Pentchev
PG: Linkage of Niemann-Pick disease type C to human chromosome 18.
Proc Natl Acad Sci U S A 1993, 90:2002–2004.
4. Vanier MT, Duthel S, Rodriguez-Lafrasse C, Pentchev P, Carstea ED: Genetic
heterogeneity in Niemann-Pick C disease: a study using somatic cell
hybridization and linkage analysis. Am J Hum Genet 1996, 58:118–125.
5. Davies JP, Ioannou YA: Topological analysis of Niemann-Pick C1 protein
reveals that the membrane orientation of the putative sterol-sensing
domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase
and sterol regulatory element binding protein cleavage-activating protein.
J Biol Chem 2000, 275:24367–24374.
6. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M,
Lobel P: Identification of HE1 as the second gene of Niemann-Pick C disease.
Science 2000, 290:2298–2301.
7. Boothe AD, Kruth HS, Weintroub H, Stivers J, Brady RO: A genetic storage
disorder in BALB/C mice with a metabolic block in esterification of
exogenous cholesterol. J Biol Chem 1984, 259:5784–5791.
8. Maue RA, Burgess RW, Wang B, Wooley CM, Seburn KL, Vanier MT, Rogers MA,
Chang CC, Chang TY, Harris BT, Graber DJ, Penatti CA, Porter DM, Szwergold BS,
Henderson LP, Totenhagen JW, Trouard TP, Borbon IA, Erickson RP: A novel
mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1
mutation comparable to commonly observed human mutations. Hum Mol
Genet 2012, 21:730–750.
9. Love S, Bridges LR, Case CP: Neurofibrillary tangles in Niemann-Pick
disease type C. Brain 1995, 118:119–129.
10. Walkley SU, Suzuki K: Consequences of NPC1 and NPC2 loss of function in
mammalian neurons. Biochim Biophys Acta 2004, 1685:48–62.
Bergamin et al. Orphanet Journal of Rare Diseases 2013, 8:34 Page 12 of 12
http://www.ojrd.com/content/8/1/3411. Vance JE, Karten B, Hayashi H: Lipid dynamics in neurons. Biochem Soc
Trans 2006, 34:399–403.
12. Zervas M, Somers KL, Thrall MA, Walkley SU: Critical role for
glycosphingolipids in Niemann–Pick disease type C. Curr Biol 2001,
11:1283–1287.
13. Beltrami AP, Cesselli D, Beltrami CA: Pluripotency rush! Molecular cues for
pluripotency, genetic reprogramming of adult stem cells, and widely
multipotent adult cells. Pharmacol Ther 2009, 124:23–30.
14. Ratajczak MZ, Zuba-Surma E, Kucia M, Poniewierska A, Suszynska M,
Ratajczak J: Pluripotent and multipotent stem cells in adult tissues.
Adv Med Sci 2012, 57:1–17.
15. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K: Comparative analysis of
mesenchymal stem cells from bone marrow, umbilical cord blood, or
adipose tissue. Stem Cells 2006, 24:1294–1301.
16. Anghileri S, Marconi S, Pignatelli A, Cifelli P, Galié M, Sbarbati A, Krampera M,
Belluzzi O, Bonetti B: Neuronal differentiation potential of human adipose-
derived mesenchymal stem cells. Stem Cells Dev 2008, 17:909–916.
17. Seo MJ, Suh SY, Bae YC, Jung JS: Differentiation of human adipose
stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res
Commun 2005, 328:258–264.
18. Case J, Horvath TL, Ballas CB, March KL, Srour EF: In vitro clonal analysis of
murine pluripotent stem cells isolated from skeletal muscle and adipose
stromal cells. Exp Hematol 2008, 36:224–234.
19. Beltrami AP, Cesselli D, Bergamin N, Marcon P, Rigo S, Puppato E, D'Aurizio F,
Verardo R, Piazza S, Pignatelli A, Poz A, Baccarani U, Damiani D, Fanin R,
Mariuzzi L, Finato N, Masolini P, Burelli S, Belluzzi O, Schneider C, Beltrami CA:
Multipotent cells can be generated in vitro from several adult human
organs (heart, liver and bone marrow). Blood 2007, 110:3438–3446.
20. Cesselli D, Beltrami AP, Rigo S, Bergamin N, D'Aurizio F, Verardo R, Piazza S,
Klaric E, Fanin R, Toffoletto B, Marzinotto S, Mariuzzi L, Finato N, Pandolfi M,
Leri A, Schneider C, Beltrami CA, Anversa P: Multipotent progenitor cells
are present in human peripheral blood. Circ Res 2009, 104:1225–1234.
21. Blanchette-Mackie EJ, Dwyer NK, Amende LM, Kruth HS, Butler JD, Sokol J,
Comly ME, Vanier MT, August JT, Brady RO: Type-C Niemann-Pick disease:
low density lipoprotein uptake is associated with premature cholesterol
accumulation in the Golgi complex and excessive cholesterol storage in
lysosomes. Proc Natl Acad Sci U S A 1988, 85:8022–8026.
22. Zhou S, Davidson C, McGlynn R, Stephney G, Dobrenis K, Vanier MT, Walkley SU:
Endosomal/lysosomal processing of gangliosides affects neuronal
cholesterol sequestration in Niemann-Pick disease type C. Am J Pathol 2011,
179:890–902.
23. Hunt DP, Jahoda C, Chandran S: Multipotent skin-derived precursors: from
biology to clinical translation. Curr Opin Biotechnol 2009, 20:522–530.
24. Fernandes KJ, McKenzie IA, Mill P, Smith KM, Akhavan M, Barnabé-Heider F,
Biernaskie J, Junek A, Kobayashi NR, Toma JG, Kaplan DR, Labosky PA,
Rafuse V, Hui CC, Miller FD: A dermal niche for multipotent adult skin-
derived precursor cells. Nat Cell Biol 2004, 6:1082–1093.
25. Gago N, Perez-Lopez V, Sanz-Jaka JP, Cormenzana P, Eizaguirre I, Bernad A,
Izeta A: Age-dependent depletion of human skin-derived progenitor
cells. Stem Cells 2009, 27:1164–1172.
26. Elleder M, Jirasek A, Smid F, Ledvinova J, Besley GTN: Niemann–Pick
disease Type C: study on the nature of the cerebral storage process.
Acta Neuropathol (Berl) 1985, 66:325–336.
27. Vanier MT: Lipid changes in Niemann-Pick disease type C brain: personal
experience and review of the literature. Neurochem Res 1999, 24:481–489.
28. Sleat DE, Wiseman JA, El-Banna M, Price SM, Verot L, Shen MM, Tint GS,
Vanier MT, Walkley SU, Lobel P: Genetic evidence for nonredundant
functional cooperativity between NPC1 and NPC2 in lipid transport.
Proc Natl Acad Sci USA 2004, 101:5886–5891.
29. March PA, Thrall MA, Brown DE, Mitchell TW, Lowenthal AC, Walkley SU:
GABAergic neuroaxonal dystrophy and other cytopathological
alterations in feline Niemann-Pick disease type C. Acta Neuropathol 1997,
94:164–172.
30. Zervas M, Dobrenis K, Walkley SU: Neurons in Niemann-Pick disease type
C accumulate gangliosides as well as unesterified cholesterol and
undergo dendritic and axonal alterations. J Neuropathol Exp Neurol 2001,
60:49–64.
31. German DC, Quintero EM, Liang CL, Ng B, Punia S, Xie C, Dietschy JM:
Selectiveneurodegeneration, without neurofibrillary tangles, in a mouse
model of Niemann-Pick C disease. J Comp Neurol. 2001, 433:415–425.32. Rodríguez-Pascau L, Coll MJ, Casas J, Vilageliu L, Grinberg D: Generation of
a human neuronal stable cell model for Niemann-pick C disease by RNA
interference. JIMD Reports 2012, 4:29–37.
33. Ordonez MP, Roberts EA, Kidwell C, Yuan S, Plaisted W, Goldstein LS:
Disruption and therapeutic rescue of autophagy in a human neuronal
model of Niemann Pick type C1. Hum Mol Genet 2012, 21:2651–2662.
doi:10.1186/1750-1172-8-34
Cite this article as: Bergamin et al.: A human neuronal model of
Niemann Pick C disease developed from stem cells isolated from
patient’s skin. Orphanet Journal of Rare Diseases 2013 8:34.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
